NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment - Scoping

STA ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over

Batch 83

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1.	Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
N/A	
_	
2.	What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
N/A	
3.	Has any change to the draft scope been agreed to highlight potential equality issues?
N/A	
4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
N/A	

Technology Appraisals: Scoping

Equality impact assessment for the proposed Single Technology Appraisal of ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over

Issue date: August 2022 1 of 2

Approved by Associate Director (name): Henry Edwards

Date: 20/07/2022

Technology Appraisals: Scoping
Equality impact assessment for the proposed Single Technology Appraisal of ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over

Issue date: August 2022 2 of 2